Familial interstitial pneumonia

Clinical Pulmonary Medicine

Volumn 21, Issue 3, 2014, Pages 120-127

  Talbert, Janet L ^a   Schwartz, David A ^a,b   Steele, Mark P ^c,d  

^a DEPARTMENT OF MEDICINE   (United States)

^b UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^c Pulmonary   (United States)

^d VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

familial interstitial pneumonia; familial pulmonary fibrosis; genetics; interstitial lung disease; MUC5B; pulmonary fibrosis; SFTPA2; SFTPC; telomerase

Indexed keywords

ELMOD 2 PROTEIN; LUNG SURFACTANT; MUCIN 5B; PROTEIN; SURFACTANT PROTEIN A; SURFACTANT PROTEIN A2; SURFACTANT PROTEIN B; SURFACTANT PROTEIN C; TELOMERASE; TELOMERASE REVERSE TRANSCRIPTASE; TERC PROTEIN; UNCLASSIFIED DRUG;

ACUTE LEUKEMIA; ALLELE; APLASTIC ANEMIA; APOPTOSIS; ARTICLE; ATELECTASIS; AUTOSOMAL DOMINANT INHERITANCE; AWARENESS; BONE MARROW DEPRESSION; BRONCHIOLITIS OBLITERANS ORGANIZING PNEUMONIA; CASE CONTROL STUDY; CELL ADHESION; CHROMOSOME 11; CHROMOSOME 5; CLINICAL CLASSIFICATION; ENVIRONMENTAL EXPOSURE; EXON; FAMILIAL INTERSTITIAL PNEUMONIA; FAMILY HISTORY; FIBROSING ALVEOLITIS; FOLLOW UP; GENE CLUSTER; GENE EXPRESSION; GENE LINKAGE DISEQUILIBRIUM; GENE LOCUS; GENE MUTATION; GENETIC ASSOCIATION; GENETIC COUNSELING; GENETIC RISK; GENETIC SCREENING; GENETIC VARIABILITY; GENETICS; HAPLOTYPE; HERITABILITY; HETEROZYGOSITY; HETEROZYGOTE; HOMOZYGOTE; HUMAN; HYPERPIGMENTATION; INCIDENCE; INFLAMMATION; INTERSTITIAL LUNG DISEASE; INTERSTITIAL PNEUMONIA; JAPANESE (PEOPLE); LEUKOPLAKIA; LINKAGE ANALYSIS; LIVER CIRRHOSIS; LIVER DISEASE; LUNG ADENOCARCINOMA; LUNG ALVEOLUS CELL; LUNG ALVEOLUS EPITHELIUM; LUNG ALVEOLUS MACROPHAGE; LUNG CANCER; LUNG DIFFUSION CAPACITY; LUNG FIBROSIS; LUNG FUNCTION; LUNG INJURY; MISSENSE MUTATION; MORTALITY; MYELODYSPLASTIC SYNDROME; NAIL DYSTROPHY; NUCLEOTIDE SEQUENCE; ONSET AGE; OSTEOPOROSIS; OXIDATIVE STRESS; PEDIGREE; PENETRANCE; PERIPHERAL BLOOD MONONUCLEAR CELL; PHENOTYPE; PREMATURITY; PREVALENCE; PROMOTER REGION; RESPIRATORY DISTRESS SYNDROME; SCREENING; SINGLE NUCLEOTIDE POLYMORPHISM; SMOKING; SURFACE TENSION; TELOMERE; TELOMERE SHORTENING; THIRD DEGREE RELATIVE; TRANSCRIPTION INITIATION SITE; UNITED KINGDOM;

EID: 84899798710     PISSN: 10680640     EISSN: 15365956     Source Type: Journal    
DOI: 10.1097/CPM.0000000000000034     Document Type: Article

References (60)

1. Steele MP, Brown KK. Genetic predisposition to respiratory diseases: infiltrative lung diseases. Respiration. 2007;74:601-608.
2. Society AT. Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. American Thoracic Society (ATS), and the European Respiratory Society (ERS). Am J Respir Crit Care Med. 2000;161:646-664.
3. American Thoracic S and European Respiratory S. American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. This joint statement of the American Thoracic Society (ATS), and the European Respiratory Society (ERS) was adopted by the ATS board of directors, June 2001 and by the ERS Executive Committee, June 2001. Am J Respir Crit Care Med. 2002;165:277-304.
4. Raghu G, Collard HR, Egan JJ, et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med. 2011;183:788-824.
5. DePinho RA, Kaplan KL. The Hermansky-Pudlak syndrome. Report of three cases and review of pathophysiology and management considerations. Medicine (Baltimore). 1985;64:192-202.
6. Riccardi VM. Von Recklinghausen neurofibromatosis. N Engl J Med. 1981;305:1617-1627.
7. Schneider EL, Epstein CJ, Kaback MJ, et al. Severe pulmonary involvement in adult Gaucher's disease. Report of three cases and review of the literature. Am J Med. 1977;63:475-480.
8. Auwerx J, Boogaerts M, Ceuppens JL, et al. Defective host defence mechanisms in a family with hypocalciuric hypercalcaemia and coexisting interstitial lung disease. Clin Exp Immunol. 1985;62:57-64.
9. Harris JO, Waltuck BL, Swenson EW. The pathophysiology of the lungs in tuberous sclerosis. A case report and literature review. Am Rev Respir Dis. 1969;100:379-387.
10. Dokal I. Dyskeratosis congenita in all its forms. Br J Haematol. 2000;110:768-779.
11. Polakoff PL, Horn BR, Scherer OR. Prevalence of radiographic abnormalities among Northern California shipyard workers. Ann N Y Acad Sci. 1979;330:333-339.
12. Selikoff IJ, Lilis R, Nicholson WJ. Asbestos disease in United States shipyards. Ann N Y Acad Sci. 1979;330:295-311.
13. Ortiz LA, Lasky J, Hamilton RF Jr, et al. Expression of TNF and the necessity of TNF receptors in bleomycin-induced lung injury in mice. Exp Lung Res. 1998;24:721-743.
14. Warshamana GS, Pociask DA, Sime P, et al. Susceptibility to asbestos-induced and transforming growth factor-beta1-induced fibroproliferative lung disease in two strains of mice. Am J Respir Cell Mol Biol. 2002;27:705-713.
15. Javaheri S, Lederer DH, Pella JA, et al. Idiopathic pulmonary fibrosis in monozygotic twins. The importance of genetic predisposition. Chest. 1980;78:591-594.
16. Bonanni PP, Frymoyer JW, Jacox RF. A family study of idiopathic pulmonary fibrosis. A possible dysproteinemic and genetically determined disease. Am J Med. 1965;39:411-421.
17. Solliday NH, Williams JA, Gaensler EA, et al. Familial chronic interstitial pneumonia. Am Rev Respir Dis. 1973;108:193-204.
18. Steele MP, Speer MC, Loyd JE, et al. Clinical and pathologic features of familial interstitial pneumonia. Am J Respir Crit Care Med. 2005;172:1146-1152.
19. Swaye P, Van Ordstrand HS, McCormack LJ, et al. Familial Hamman-Rich syndrome. Report of eight cases. Dis Chest. 1969;55:7-12.
20. Tsukahara M, Kajii T. Interstitial pulmonary fibrosis in two sisters. Possible autosomal recessive inheritance. Jinrui Idengaku Zasshi. 1983;28:263-267.
21. Lee HL, Ryu JH, Wittmer MH, et al. Familial idiopathic pulmonary fibrosis: clinical features and outcome. Chest. 2005;127:2034-2041.
22. Marshall RP, Puddicombe A, Cookson WO, et al. Adult familial cryptogenic fibrosing alveolitis in the United Kingdom. Thorax. 2000;55:143-146.
23. Seibold MA, Wise AL, Speer MC, et al. A common MUC5B promoter polymorphism and pulmonary fibrosis. N Engl J Med. 2011;364:1503-1512.
24. Hodgson U, Laitinen T, Tukiainen P. Nationwide prevalence of sporadic and familial idiopathic pulmonary fibrosis: evidence of founder effect among multiplex families in Finland. Thorax. 2002;57:338-342.
25. Loyd JE. Pulmonary fibrosis in families. Am J Respir Cell Mol Biol. 2003;29:S47-S50.
26. van Moorsel CH, van Oosterhout MF, Barlo NP, et al. Surfactant protein C mutations are the basis of a significant portion of adult familial pulmonary fibrosis in a dutch cohort. Am J Respir Crit Care Med. 2010;182:1419-1425.
27. Garcia-Sancho C, Buendia-Roldan I, Fernandez-Plata MR, et al. Familial pulmonary fibrosis is the strongest risk factor for idiopathic pulmonary fibrosis. Respir Med. 2011;105: 1902-1907.
28. Fan LL, Deterding RR, Langston C. Pediatric interstitial lung disease revisited. Pediatr Pulmonol. 2004;38:369-378.
29. Deutsch GH, Young LR, Deterding RR, et al. Diffuse lung disease in young children: application of a novel classification scheme. Am J Respir Crit Care Med. 2007;176:1120-1128.
30. Hamvas A, Cole FS, Nogee LM. Genetic disorders of surfactant proteins. Neonatology. 2007;91:311-317.
31. Whitsett JA, Wert SE, Weaver TE. Alveolar surfactant homeostasis and the pathogenesis of pulmonary disease. Annu Rev Med. 2010;61:105-119.
32. Bullard JE, Nogee LM. Heterozygosity for ABCA3 mutations modifies the severity of lung disease associated with a surfactant protein C gene (SFTPC) mutation. Pediatr Res. 2007;62: 176-179.
33. Nogee LM, Dunbar AE III, Wert SE, et al. A mutation in the surfactant protein C gene associated with familial interstitial lung disease. N Engl J Med. 2001;344:573-579.
34. Thomas AQ, Lane K, Phillips J III, et al. Heterozygosity for a surfactant protein C gene mutation associated with usual interstitial pneumonitis and cellular nonspecific interstitial pneumonitis in one kindred. Am J Respir Crit Care Med. 2002;165:1322-1328.
35. Fernandez BA, Fox G, Bhatia R, et al. A Newfoundland cohort of familial and sporadic idiopathic pulmonary fibrosis patients: clinical and genetic features. Respir Res. 2012;64:1-10.
36. Markart P, Ruppert C, Wygrecka M, et al. Surfactant protein C mutations in sporadic forms of idiopathic interstitial pneumonias. Eur Respir J. 2007;29:134-137.
37. Lawson WE, Grant SW, Ambrosini V, et al. Genetic mutations in surfactant protein C are a rare cause of sporadic cases of IPF. Thorax. 2004;59:977-980.
38. Wang Y, Kuan PJ, Xing C, et al. Genetic defects in surfactant protein A2 are associated with pulmonary fibrosis and lung cancer. Am J Hum Genet. 2009;84:52-59.
39. Dokal I. Dyskeratosis congenita. Hematol Am Soc Hematol Educ Program. 2011;2011:480-486.
40. Armanios M. Syndromes of telomere shortening. Annu Rev Genomics Hum Genet. 2009;10:45-61.
41. Calado RT, Young NS. Telomere diseases. N Engl J Med. 2009;361:2353-2365.
42. Garcia CK, Wright WE, Shay JW. Human diseases of telomerase dysfunction: insights into tissue aging. Nucleic Acids Res. 2007;35:7406-7416.
43. Alder JK, Chen JJ, Lancaster L, et al. Short telomeres are a risk factor for idiopathic pulmonary fibrosis. Proc Natl Acad Sci USA. 2008;105:13051-13056.
44. Armanios MY, Chen JJ, Cogan JD, et al. Telomerase mutations in families with idiopathic pulmonary fibrosis. N Engl J Med. 2007;356:1317-1326.
45. Tsakiri KD, Cronkhite JT, Kuan PJ, et al. Adult-onset pulmonary fibrosis caused by mutations in telomerase. Proc Natl Acad Sci USA. 2007;104:7552-7557.
46. Diaz de Leon A, Cronkhite JT, Katzenstein AL, et al. Telomere lengths, pulmonary fibrosis and telomerase (TERT) mutations. PLoS One. 2010;5:e10680.
47. Cronkhite JT, Xing C, Raghu G, et al. Telomere shortening in familial and sporadic pulmonary fibrosis. Am J Respir Crit Care Med. 2008;178:729-737.
48. Fingerlin TE, Murphy E, Zhang W, et al. Genome-wide association study identifies multiple susceptibility loci for pulmonary fibrosis. Nat Genet. 2013;45:613-620.
49. Vulliamy T, Marrone A, Dokal I, et al. Association between aplastic anaemia and mutations in telomerase RNA. Lancet. 2002;359:2168-2170.
50. Yamaguchi H, Calado RT, Ly H, et al. Mutations in TERT, the gene for telomerase reverse transcriptase, in aplastic anemia. N Engl J Med. 2005;352:1413-1424.
51. Yamaguchi H, Baerlocher GM, Lansdorp PM, et al. Mutations of the human telomerase RNA gene (TERC) in aplastic anemia and myelodysplastic syndrome. Blood. 2003;102:916-918.
52. Calado RT, Brudno J, Mehta P, et al. Constitutional telomerase mutations are genetic risk factors for cirrhosis. Hepatology. 2011;53:1600-1607.
53. Armanios M. Telomerase and idiopathic pulmonary fibrosis. Mut Res. 2012;730:52-58.
54. Hodgson U, Pulkkinen V, Dixon M, et al. ELMOD2 is a candidate gene for familial idiopathic pulmonary fibrosis. Am J Hum Genet. 2006;79:149-154.
55. Pulkkinen V, Bruce S, Rintahaka J, et al. ELMOD2, a candidate gene for idiopathic pulmonary fibrosis, regulates antiviral responses. FASEB J. 2010;24:1167-1177.
56. Zhang Y, Noth I, Garcia JG, et al. A variant in the promoter of MUC5B and idiopathic pulmonary fibrosis. N Engl J Med. 2011;364:1576-1577.
57. Noth Iea. Genetic variants associated with idiopathic pulmonary fibrosis susceptibility and mortality: a genome-wide association study. Lancet Respir Med. 2013;1:309-317.
58. Peljto AL, Zhang Y, Fingerlin TE, et al. Association between the MUC5B promoter polymorphism and survival in patients with idiopathic pulmonary fibrosis. JAMA. 2013;1-8.
59. Mushiroda T, Wattanapokayakit S, Takahashi A, et al. A genomewide association study identifies an association of a common variant in TERT with susceptibility to idiopathic pulmonary fibrosis. J Med Genet. 2008;45: 654-656.
60. Genetic Information Nondiscrimination Act of 2008, Public Law 110-233, 42 USC, 122 STAT 181, 2008